异柠檬酸脱氢酶1突变通过绝缘子破坏激活PDGFRA驱动急性髓系白血病发生
该研究探讨IDH1 p.R132H突变通过改变三维DNA结构激活癌基因在急性髓系白血病(AML)中的作用。公共RNA-Seq数据显示IDH1突变患者PDGFRA上调且预后不良,DNA甲基化分析发现PDGFRA上游CTCF锚点CpG高甲基化,并在CRISPR细胞及2-HG处理中证实PDGFRA表达升高、PDGFRA-CTCF甲基化增加和CTCF结合减少。IDH1突变细胞对达沙替尼更敏感,一例难治性IDH1突变AML患者达沙替尼治疗后原始细胞计数减少。
要点
- IDH1突变患者PDGFRA上调且与预后不良相关。
- IDH1 p.R132H导致CTCF锚点高甲基化,破坏DNA环化和PDGFRA绝缘。
- 达沙替尼可能为IDH1突变AML提供新治疗策略。
核心结论
- IDH1 p.R132H突变导致CTCF高甲基化,破坏DNA环化和PDGFRA绝缘,导致IDH1突变AML中PDGFRA上调。
- 达沙替尼治疗可能为IDH1突变AML提供新的治疗策略。
研究设计与样本
- 研究利用公共RNA-Seq数据、DNA甲基化分析、AML CRISPR细胞模型及外源性2-HG处理,并结合一例难治性IDH1突变AML患者治疗观察。
主要发现
- 公共RNA-Seq数据显示IDH1突变患者PDGFRA上调,且与预后不良相关。
- DNA甲基化分析发现IDH1突变患者PDGFRA上游CTCF锚点内CpG高甲基化。
- 在杂合IDH1 p.R132H突变的AML CRISPR细胞及外源性2-HG处理中,证实PDGFRA表达升高、PDGFRA-CTCF甲基化增加和CTCF结合减少。
- IDH1突变细胞对酪氨酸激酶抑制剂达沙替尼敏感性更高。
- 一例难治性IDH1突变AML患者达沙替尼治疗后原始细胞计数减少。
临床怎么用
- 作者认为达沙替尼治疗可能为IDH1突变AML提供新的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is characterized by complex molecular alterations and driver mutations. Elderly patients show increased frequencies of IDH mutations with high chemoresistance and relapse rates despite recent therapeutic advances. Besides being associated with global promoter hypermethylation, IDH1 mutation facilitated changes in 3D DNA-conformation by CTCF-anchor methylation and upregulated oncogene expression in glioma, correlating with poor prognosis. Here, we investigated the role of IDH1 p.R132H mutation in altering 3D DNA-architecture and subsequent oncogene activation in AML. Using public RNA-Seq data, we identified upregulation of tyrosine kinase PDGFRA in IDH1-mutant patients, correlating with poor prognosis. DNA methylation analysis identified CpG hypermethylation within a CTCF-anchor upstream of PDGFRA in IDH1-mutant patients. Increased PDGFRA expression, PDGFRA-CTCF methylation and decreased CTCF binding were confirmed in AML CRISPR cells with heterozygous IDH1 p.R132H mutation and upon exogenous 2-HG treatment. IDH1-mutant cells showed higher sensitivity to tyrosine kinase inhibitor dasatinib, which was supported by reduced blast count in a patient with refractory IDH1-mutant AML after dasatinib treatment. Our data illustrate that IDH1 p.R132H mutation leads to CTCF hypermethylation, disrupting DNA-looping and insulation of PDGFRA, resulting in PDGFRA upregulation in IDH1-mutant AML. Treatment with dasatinib may offer a novel treatment strategy for IDH1-mutant AML.
引用
- Steinhäuser S, Silva P, Lenk L, et al. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML). Leukemia. 2022. PMID: 36411356. doi:10.1038/s41375-022-01751-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。